A double-blind comparison of acitretin and etretinate in the treatment of Darier's disease.
The objective of this double-blind study was to compare the therapeutic effects of acitretin with those of etretinate in patients with Darier's disease. Twenty-six patients (10 males and 16 females) were included in the study. Patients were treated with 30 mg daily for the first 4 weeks and with an individually adjusted dose (10-50 mg/day) for the subsequent 12 weeks. Remission or marked improvement was obtained in 10 of the 13 acitretin-treated patients and in 8 of the 11 etretinate-treated patients who completed the 16-week treatment. The usual mucocutaneous adverse reactions of retinoids were observed in all but one patient. There were no significant differences between treatment groups with regard to the incidence of these reactions.
Department of Dermatology, Gentofte Hospital, Copenhagen, Denmark.
J
J
Christophersen
J M
JM
Geiger
P
P
Danneskiold-Samsoe
K
K
Kragballe
F G
FG
Larsen
G
G
Laurberg
J
J
Serup
K
K
Thomsen
D017255:Acitretin; D000293:Adolescent; D000328:Adult; D000368:Aged; D007644:Darier Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005050:Etretinate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014212:Tretinoin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014212:Tretinoin; D005050:Etretinate; D017255:Acitretin